Down 42% from Oct 20 to Oct 30 while the S&P 500 fell 2%.
−3Long-term trend
Follow AVTX's news. Pro members can get an alert when Avalo Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 12.9% a day with no profit behind it |
| Latest filing | 10-Q, Aug 6 |
After its last 4 reports it closed -1.7% on average, higher 1 of 4 times.
The company says its cash lasts into 2029 (8-K, Aug 6).
CFO Christopher Ryan Sullivan sold 12,394 shares on Sep 16, under a planned sale. 21 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
AVTX is #256 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 256 |
Expected to report Thu Nov 12, before the open (in 10 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The difference was mainly driven by a $12.2 million increase in operating expenses due to the $9.3 million increase in research and development expenses and $2.9 million increase in general and administrative expenses, as discussed above.”
AVTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Research and development expenses were $23.4 million for the second quarter of 2026, an increase of $9.3 million from the second quarter of 2025, driven by the recognition of a $10.0 million development milestone for abdakibart, as well as costs related to and supporting the development of abdakibart in HS.”
From its results filing (SEC filing · Aug 6)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -5.2% | -0.7% | +3.8% |
| May 13, 2026 | +1.4% | -0.5% | -18.4% |
| Mar 23, 2026 | 0.0% | +0.6% | +3.5% |
Sales grew in one of the last seven years, to $59K in 2025. It lost money in each of the eight years.
One insider sold $52K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AVTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
“We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad.”
AVTX scores -7 today, which Breakaway calls Poor. It is #256 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 42% from Oct 20 to Oct 30 while the S&P 500 fell 2%. Shares: 91.2% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AVTX scores -7 today, which Breakaway calls Poor (below zero). That is #256 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AVTX's -7.
One insider sold $52K across 1 filing in the last 6 months. No open-market buys on record. The newest is Jennifer Riley, Chief Strategy Officer, who sold $52K on Aug 11.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.